References

1 Lapostolle F, Surget V, Borron SW, et al. Severe pulmonary embolism associated with air travel. N Engl J Med. 2001;345(11):779-783.

2 Moll S, Mackman N. Venous thromboembolism: a need for more public awareness and research into mechanisms. Arterioscler Thromb Vasc Biol. 2008;28(3):367-369.

3 1. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6)(suppl):381S-453S.

4 Lip GY, Tse HF. Management of atrial fibrillation. Lancet. 2007;370(9587):604-618.

5 Fuster V, Moreno PR, Fayad ZA, Corti R, Badimon JJ. Atherothrombosis and high-risk plaque: part I: evolving concepts. J Am Coll Cardiol. 2005;46(6):937-954.

6 Colman RW, Clowes AW, George JN, Goldhaber SZ, Marder VJ. Overview of hemostasis. In: Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2006:3-16.

7 Tran H, Ginsberg J. Anticoagulant therapy for major arterial and venous thromboembolism. In: Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2006:1673-1688.

8 Tapson VF. Acute pulmonary embolism. N Engl J Med. 2008;358(10):1037-1052.

9 Miller KL, Pollack CV Jr, Peterson ED. Moving from evidence to practice in the care of patients who have acute coronary syndrome. Cardiol Clin. 2006;24(1):87-102.

10 Adams GL, Manson RJ, Turner I, Sindram D, Lawson JH. The balance of thrombosis and hemorrhage in surgery. Hematol Oncol Clin North Am. 2007;21(1):13-24.

11 Heit JA. Venous thromboembolism: disease burden, outcomes and risk factors. J Thromb Haemost. 2005;3(8):1611-1617.

12 Cohen AT, Agnelli G, Anderson FA, et al; VTE Impact Assessment Group in Europe (VITAE). Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007;98(4):756-764.

13 Mann KG, Butenas S, Brummel K. The dynamics of thrombin formation. Arterioscler Thromb Vasc Biol. 2003;23(1):17-25.

14 Colman RW, Marder VJJ, Clowes AW. Overview of coagulation, fibrinolysis and their regulation. In: Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ, eds. iHemostasis and Thrombosis: Basic Principles and Clinical Practice. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2006:17-20.

15 Hoffman M, Monroe DM. Coagulation 2006: a modern view of hemostasis. Hematol Oncol Clin North Am. 2007;21(1):1-11.

16 Mann KG, Brummel K, Butenas S. What is all that thrombin for? J Thromb Haemost. 2003;1(7):1504-1514.

17 Turpie AG. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol. 2007;27(6):1238-1247.

18 Waldo AL. Anticoagulation: stroke prevention in patients with atrial fibrillation. Med Clin North Am. 2008;92(1):143-159, xi.

19 Harkess JW, Arthroplasty of hip. In: Canale ST, ed. Campbell’s Operative Orthopedics. 10th ed. Philadelphia, PA: Mosby, Inc; 2003. Available at www.mdconsult.com. Accessed February 12, 2008.

20 Bates SM, Ginsberg JS. Clinical practice. Treatment of deep-vein thrombosis. N Engl J Med. 2004;351(3):268-277.

21 Fitzmaurice DA, Murray E. Thromboprophylaxis for adults in hospital. BMJ. 2007;334(7602):1017-1018.

22 Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114(7):e257-e354.

23 Bassand JP, Hamm CW, Ardissino D, et al; Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007;28(13):1598-1660.

24 Rosamond W, Flegal K, Furie K, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics―2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117(4):e25-e146.

25 Turpie AG, Chin BS, Lip GY. Venous thromboembolism: pathophysiology, clinical features, and prevention. BMJ. 2002;325(7369):887-890.

26 Merli GJ. Pathophysiology of venous thrombosis, thrombophilia, and the diagnosis of deep vein thrombosis-pulmonary embolism in the elderly. Clin Geriatr Med. 2006;22(1):75-92, viii-ix.

27 Jerjes-Sanchez C. Venous and arterial thrombosis: a continuous spectrum of the same disease? Eur Heart J. 2005; 26(1):3-4.

28 Lip GY, Blann AD. Thrombogenesis and fibrinolysis in acute coronary syndromes. Important facets of a prothrombotic or hypercoagulable state? J Am Coll Cardiol. 2000;36(7):2044-2046.

29 1. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. S3-Leitlinie. Prophylaxe der venösen Thromboembolie (VTE) Version vom 18. März 2009.

30 Alikhan R, Cohen AT, Combe S, et al; MEDENOX Study. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med. 2004;164(9):963-968.

31 Kucher N, Koo S, Quiroz R, et al. Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med. 2005;352(10):969-977.

32 Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med. 2001;344(16):1222-1231.

33 Padanilam BJ, Prystowsky EN. Atrial fibrillation: goals of therapy and management strategies to achieve the goals. Med Clin North Am. 2008;92(1):217-235, xii-xiii.

34 Kannel WB, Benjamin EJ. Status of the epidemiology of atrial fibrillation. Med Clin North Am. 2008 ;92(1):17-40, ix.

35 Li-Saw-Hee FL, Blann AD, Lip GY. A cross-sectional and diurnal study of thrombogenesis among patients with chronic atrial fibrillation. J Am Coll Cardiol. 2000;35(7):1926-1931.

36 British Heart Foundation. European Cardiovascular Disease Statistics, 2008. http://www.heartstats.org/datapage.asp?id=7683. Accessed March 8, 2008.

37 National Cholesterol Education Program, Third Report of the NCEP Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATPIII). National Cholesterol Education Program. National Institutes of Health, National Heart, Lung, and Blood Institute. NIH Publication No. 02-5215. September 2002.

38 Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002;347(13):969-974.

39 Gorelick PB. Epidemiology of transient ischemic attack and ischemic stroke in patients with underlying cardiovascular disease. Clin Cardiol. 2004;27(5)(suppl 2), II4-II11.

40 Anderson FA Jr, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med. 1991;151(5):933-938.

41 Buller HR, Sohne M, Middeldorp S. Treatment of venous thromboembolism. J Thromb Haemost. 2005;3(8):1554-1560.

42 Ramzi DW, Leeper KV. DVT and pulmonary embolism: Part I. Diagnosis. Am Fam Physician. 2004;69(12):2829-2836.

43 Kearon C, Hirsh J. Cardiovascular medicine: XVIII. Venous thromboembolism. In: Dale DC, ed. ACP Medicine. New York, NY: WebMD, Inc; 2007:1-15. http://www.acpmedicine.com/acp_home.htm. Accessed February 12, 2008.

44 Stern JB, Abehsera M, Grenet D, et al. Detection of pelvic vein thrombosis by magnetic resonance angiography in patients with acute pulmonary embolism and normal lower limb compression ultrasonography. Chest. 2002;122(1):115-121.

45 Wells PS, Anderson DR, Bormanis J, et al. Value of assessment of pretest probability of deep-vein thrombosis in clinical management. Lancet. 1997;350(9094):1795-1798.

46 Saad WE, Saad N. Computer tomography for venous thromboembolic disease. Radiol Clin North Am. 2007;45(3):423-445.

47 The PIOPED Investigators. Value of the ventilation/perfusion scan in acute pulmonary embolism. Results of the prospective investigation of pulmonary embolism diagnosis (PIOPED). The PIOPED Investigators. JAMA. 1990;263(20):2753-2759.

48 Blann AD, Lip GY. Venous thromboembolism. BMJ. 2006;332(7535):215-219.

49 Agmon Y, Khandheria BK, Gentile F, Seward JB. Echocardiographic assessment of the left atrial appendage. J Am Coll Cardiol. 1999;34(7):1867-1877.

50 Rastegar R, Harnick DJ, Weidemann P, et al. Spontaneous echo contrast videodensity is flow-related and is dependent on the relative concentrations of fibrinogen and red blood cells. J Am Coll Cardiol. 2003;41(4):603-610.

51 Anderson JL. ST segment elevation myocardial infarction and complications of myocardial infarction. In: Goldman L, Ausiello D, eds. Cecil Medicine. 23rd ed. Philadelphia, PA: Saunders Elsevier; 2007. www.mdconsult.com. Accessed February 12, 2008.

52 Waters DH. Acute coronary syndrome: unstable angina and non-ST segment elevation myocardial infarction. In: Goldman L, Ausiello D, eds. Cecil Medicine. 23rd ed. Philadelphia, PA: Saunders Elsevier; 2007. www.mdconsult.com. Accessed February 12, 2008.

53 Milner KA, Funk M, Richards S, Wilmes RM, Vaccarino V, Krumholz HM. Gender differences in symptom presentation associated with coronary heart disease. Am J Cardiol. 1999;84(4):396-399.

54 Tapson VF, Decousus H, Pini M, et al; IMPROVE Investigators. Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. Chest. 2007;132(3):936-945.

55 Kakkar AK. Prevention of venous thromboembolism in general surgery.In: Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2006:1361-1367.

56 Motte S, Samama CM, Guay J, Barré J, Borg JY, Rosencher N. Prevention of postoperative venous thromboembolism. Risk assessment and methods of prophylaxis. Can J Anaesth. 2006;53(6)(suppl):S68-S79.

57 Cohen AT, Tapson VF, Bergmann JF, et al; ENDORSE Investigators. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet. 2008;371(9610):387-394.

58 White RH, Zhou H, Romano PS. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost. 2003;90(3):446-455.

59 Planes A, Vochelle N, Darmon JY, Fagola M, Bellaud M, Huet Y. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet. 1996;348(9022):224-228.

60 Nicolaides AN, Fareed J, Kakkar AK, et al. Prevention and treatment of venous thromboembolism. International Consensus Statement (guidelines according to scientific evidence). Int Angiol. 2006;25(2):101-161.

61 Goldhaber SZ, Tapson VF; DVT FREE Steering Committee. A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol. 2004;93(2):259-262.

62 Lyman GH, Khorana AA, Falanga A, et al; American Society of Clinical Oncology. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007;25(34):5490-5505.

63 Goldhaber SZ. Pulmonary embolism. Lancet. 2004;363(9417):1295-1305.

64 Francis CW. Clinical practice. Prophylaxis for thromboembolism in hospitalized medical patients. N Engl J Med. 2007;356(14):1438-1444.

65 White RH. The epidemiology of venous thromboembolism. Circulation. 2003;107(23)(suppl 1):I4-I8.

66 Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160(6):809-815.

67 Cohen AT, Davidson BL, Gallus AS, et al; ARTEMIS Investigators. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ. 2006;332(7537):325-329.

68 Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med. 1999;341(11):793-800.

69 Dentali F, Douketis JD, Gianni M, Lim W, Crowther MA. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med. 2007;146(4):278-288.

70 Levine MN, Lee AYY, Kakkar AK. Cancer and Thrombosis. In: Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2006:1251-1262.

71 Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293(6):715-722.

72 Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166(4):458-464

73 Kearon C. Natural history of venous thromboembolism. Circulation. 2003;107(23)(suppl 1):I22-I30.

74 Kahn SR. The post-thrombotic syndrome: the forgotten morbidity of deep venous thrombosis. J Thromb Thrombolysis. 2006;21(1):41-48.

75 Haenen JH, Janssen MC, van Langen H, et al. The postthrombotic syndrome in relation to venous hemodynamics, as measured by means of duplex scanning and strain-gauge plethysmography. J Vasc Surg. 1999;29(6):1071-1076.

76 Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996;125(1):1-7.

77 Pengo V, Lensing AW, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med. 2004;350(22):2257-2264.

78 Fedullo PF, Auger WR, Kerr KM, Rubin LJ. Chronic thromboembolic pulmonary hypertension. N Engl J Med. 2001;345(20):1465-1472.

79 Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001; 285(18):2370-2375.

80 Wyse DG, Waldo AL, DiMarco JP, et al; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347(23):1825-1833.

81 Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology. 2007;69(6):546-554.

82 Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864-2870.

83 Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation. 2007;116(7):e148-e304.

84 Vickrey BG, Rector TS, Wickstrom SL, et al. Occurrence of secondary ischemic events among persons with atherosclerotic vascular disease. Stroke. 2002;33(4):901-906.

85 Fletcher GF, Bufalino V, Costa F, et al. Efficacy of drug therapy in the secondary prevention of cardiovascular disease and stroke. Am J Cardiol. 2007;99(6C):1E-35E.

86 Vesely MR, Kelemen MD. Cardiac risk assessment: matching intensity of therapy to risk. Cardiol Clin. 2006;24(1):67-78.

87 Bavry AA, Kumbhani DJ, Helton TJ, Borek PP, Mood GR, Bhatt DL. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med. 2006;119(12):1056-1061.

88 Spyropoulos AC. Investigational treatments of venous thromboembolism. Expert Opin Investig Drugs. 2007;16(4):431-440.

89 Haas S. New oral Xa and IIa inhibitors: updates on clinical trial results. J Thromb Thrombolysis. 2008;25(1):52-60.

90 Spencer FA, Emery C, Lessard D, et al. The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med. 2006;21(7):722-727.

91 Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest. 2001;119(1)(suppl):132S-175S.

92 Hirsh J, O'Donnell M, Weitz JI. New anticoagulants. Blood. 2005;105(2):453-463.

93 Hirsh J, Dalen J, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 2001;119(1)(suppl):8S-21S.

94 Verstraete M, Prentice CR, Samama M, Verhaeghe R. A European view on the North American fifth consensus on antithrombotic therapy. Chest. 2000;117(6):1755-1770.

95 Mackman N. Triggers, targets and treatments for thrombosis. Nature. 2008;451(7181):914-918.

96 Haines S, Racine E, Zeolla M. Venous thromboembolism. In: DiPiro J, Talbert R, Yee G, Matzke G, Wells G, Posey L, eds. Pharmacotherapy: A Pathophysiologic Approach. 5th ed. New York, NY: McGraw-Hill Companies, Inc.; 2002:337-373.

97 Shurin SB, Nabel EG. Pharmacogenomics—ready for prime time? N Engl J Med. 2008;358(10):1061-1063.

98 Schwarz UI, Ritchie MD, Bradford Y, et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med. 2008;358(10):999-1008.

99 Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med. 1998;158(15):1641-1647.

100 Mueller RL, Scheidt S. History of drugs for thrombotic disease. Discovery, development, and directions for the future. Circulation. 1994;89(1):432-449.

101 Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, and Weitz JI. Parenteral Anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest. 2008;133(6)(suppl): 141S–159S.

102 Bick RL, Frenkel EP, Walenga J, Fareed J, Hoppensteadt DA. Unfractionated heparin, low molecular weight heparins, and pentasaccharide: basic mechanism of actions, pharmacology, and clinical use. Hematol Oncol Clin North Am. 2005;19(1):1-51, v.

103 Wu CL. Regional anesthesia and anticoagulation. J Clin Anesth. 2001;13(1):49-58.

104 Warkentin TE, Greinacher A, Koster A, and Lincoff AM. Treatment and Prevention of Heparin-Induced Thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6)(suppl):340S-380S.

105 Weitz JI, Bates SM. New anticoagulants. J Thromb Haemost. 2005;3(8):1843-1853.

106 Frenkel EP, Shen YM, Haley BB. The direct thrombin inhibitors: their role and use for rational anticoagulation. Hematol Oncol Clin North Am. 2005;19(1):119-145, v-vii.

107 Messmore HL Jr, Jeske WP, Wehrmacher W, et al. Antiplatelet agents: current drugs and future trends. Hematol Oncol Clin North Am. 2005;19(1):87-117, vi.

108 Roth GJ. Antiplatelet therapy. In: Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2006:1725-1737.

109 Plavix [package insert]. Bridgewater, NJ: Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership; 2007.

110 Beebe HG, Dawson DL, Cutler BS, et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med. 1999;159(17):2041-2050.

111 National Collaborating Centre for Acute Care. Venous Thromboembolism: Reducing the Risk for Surgical Inpatients. London, England: Royal College of Surgeons of England; 2007:1-163.

112 Roderick P, Ferris G, Wilson K, et al. Towards evidence-based guidelines for the prevention of venous thromboembolism: systematic reviews of mechanical methods, oral anticoagulation, dextran and regional anaesthesia as thromboprophylaxis. Health Technol Assess. 2005;9(49). :iii-iv, ix-x, 1-78.

113 Schulz SL, Stechemesser B, Seeberger U, Meyer D, Kesselring C. Graduated compression stockings for the prevention of venous thromboembolism in surgical patients in the age of low molecular weight heparins. J Thromb Haemost. 2005;3(10):2363-2365.

114 Cohen AT, Skinner JA, Warwick D, Brenkel I. The use of graduated compression stockings in association with fondaparinux in surgery of the hip. A multicentre, multinational, randomised, open-label, parallel-group comparative study. J Bone Joint Surg Br. 2007;89(7):887-892.

115 Agnelli G. Prevention of venous thromboembolism in surgical patients. Circulation.2004;110(24)(suppl 1):IV4-IV12.

116 Wilson NV, Das SK, Kakkar VV, et al. Thrombo-embolic prophylaxis in total knee replacement. Evaluation of the A-V Impulse System. J Bone Joint Surg Br. 1992;74(1):50-52.

117 Warwick D, Harrison J, Whitehouse S, Mitchelmore A, Thornton M. A randomised comparison of a foot pump and low-molecular-weight heparin in the prevention of deep-vein thrombosis after total knee replacement. J Bone Joint Surg Br. 2002;84(3):344-350.

118 Anderson FA Jr, Hirsh J, White K, Fitzgerald RH Jr; Hip and Knee Registry Investigators. Temporal trends in prevention of venous thromboembolism following primary total hip or knee arthroplasty 1996-2001: findings from the Hip and Knee Registry. Chest.2003;124(6)(suppl):349S-356S.

119 Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ; PREVENT Medical Thromboprophylaxis Study Group. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;110(7):874-879.

120 Lee AY, Levine MN, Baker RI, et al;.Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146-153.

121 Kahn SR, Shbaklo H, Shapiro S, et al; SOX Trial Investigators. Effectiveness of compression stockings to prevent the post-thrombotic syndrome (the SOX Trial and Bio-SOX biomarker substudy): a randomized controlled trial. BMC Cardiovasc Disord. 2007;7:21. http://www.biomedcentral.com/1471-2261/7/21. Accessed April 30, 2008.

122 Decousus H, Leizorovicz A, Parent F, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med. 1998;338(7):409-415.

123 Kucher N, Goldhaber SZ. Risk stratification of acute pulmonary embolism. Semin Thromb Hemost. 2006;32(8):838-847.

124 Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6)(suppl):454S-545S.

125 Hart RG, Halperin JL. Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention. Ann Intern Med.1999;131(9):688-695.

126 Lip GY, Lim HS. Atrial fibrillation and stroke prevention. Lancet Neurol. 2007;6(11):981-993.

127 Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857-867.

128 Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007;115(21):2689-2696.

129 Gelfand EV, Cannon CP. Acute Coronary Syndrome. In: Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2006:1387-1404.

130 Smith SC Jr, Allen J, Blair SN, et al; AHA/ACC; National Heart, Lung, and Blood Institute. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006;113(19):2363-2372.

131 Ansell J. Factor Xa or thrombin: is factor Xa a better target? J Thromb Haemost. 2007;5(suppl 1):60-64.

132 Novel oral anticoagulant Pradaxa (dabigatran etexilate) approved by the European Commission [press release]. http://www.fiercebiotech.com/press-releases/novel-oral-anticoagulant-pradaxa-dabigatran-etexilate-approved-european-commission. Accessed April 10, 2008.

133 Rickles FR, Patierno S, Fernandez PM. Tissue factor, thrombin, and cancer. Chest. 2003;124(3)(suppl):58S-68S.

134 Suo Z, Citron BA, Festoff BW. Thrombin: a potential proinflammatory mediator in neurotrauma and neurodegenerative disorders. Curr Drug Targets Inflamm Allergy. 2004;3(1):105-114.

135 Bates SM, Weitz JI. New antithrombotic drugs. In: Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2006:1763-1783.

136 Rich JD, Wiviott SD. New antiplatelet therapies for acute coronary syndromes. Curr Cardiol Rep. 2007;9(4):303-311.

137 Yoshida S, Sudo T, Niimi M, et al. Inhibition of collagen-induced platelet aggregation by anopheline antiplatelet protein, a saliva protein from a malaria vector mosquito. Blood. 2008;111(4):2007-2014.

138 Gachet C. The platelet P2 receptors as molecular targets for old and new antiplatelet drugs. Pharmacol Ther. 2005;108(2):180-192.

139 Leger AJ, Jacques SL, Badar J, et al. Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis. Circulation. 2006;113(9):1244-1254.

140 Guyton AC, Hall JE. Textbook of Medical Physiology. 10th ed. Philadelphia, PA: WB Saunders, Co.; 2000.

141 Chung CS, Caplan LR. Neurovascular disorders. In: Goetz CG, ed. Textbook of Clinical Neurology. 2nd ed. Philadelphia, PA: Elsevier Science; 2003:991-1016.

142 Schoen FJ. Blood vessels. In: Kumar V, Abbas AK, Fausto N, eds. Robbins and Cotran Pathologic Basis of Disease. 7th ed. Philadelphia, PA: Elsevier, Inc.; 2005. Available at www.mdConsult.com. Accessed March 17, 2008.

143 Goldhaber SZ. Preventing pulmonary embolism and deep vein thrombosis: a 'call to action' for vascular medicine specialists. J Thromb Haemost 2007;5(8):1607-1609.

144 Heit JA, Cohen AT, Anderson FAJ, VTE Impact Assessment Group. Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. [Abstract 910]. Blood 2005;106(11):267a.

145 House of Commons Health Committee. The prevention of venous thromboembolism in hospitalised patients. http://www.publications.parliament.uk/pa/cm200405/cmselect/cmhealth/99/99.pdf

146 Ferri F. Ferri's Clinical Advisor. 2004: Instant diagnosis and treatment. 6th ed. St Louis, MO: Mosby; 2003.

147 Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med.1998;158(6):585-593.

148 Kearon C. Natural history of venous thromboembolism. Semin Vasc Med. 2001;1(1):27-37.

149 Sandler DA. Martin JF. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? J R Soc Med. 1989;82(4): 203-205.

150 Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983– 988.

151 Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol. 1994;74(3):236-241.

152 Kakkar AK, Brenner B, Dahl OE, et al; RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet2008;372(9632):31-39.

153 Bayer’s Novel Anticoagulant Xarelto® now also Approved in the EU [press release]. Leverkusen, Germany: Bayer HealthCare AG; October 1, 2008; http://www.xarelto.com/html/press/pdf/2008-0442E.pdf . Accessed March 8, 2011.

154 Bristol-Myers Squibb and Pfizer Provide Update on Apixaban Clinical Development Program [press release]. PRINCETON, N.J. & NEW YORK: Bristol-Myers Squibb Company & Pfizer Inc.; August 26, 2008; http://www.businesswire.com/news/home/20081211006335/en/Bristol-Myers-Squibb-Pfizer-Provide-Update-Apixaban-Clinical . Accessed March 8, 2011.

155 AAOS [American Academy of Orthopedic Surgeons]. Clinical guideline on prevention of pulmonary embolism in patients undergoing total hip or knee arthroplasty. Adopted by the American Academy of Orthopedic Surgeons Board of Directors; 2007.

156 Ahrens I, Lip GY, Pete K. New oral anticoagulant drugs in cardiovascular disease. Thomb Haemost. 2010;104(1):49-60.

157 Angiomax [package insert]. Parsippany, NJ: The Medicines Company; 2005.

158 Argatroban [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2009.

159 ARYx Therapeutics, Inc. Efficacy of tecarfarin mirrors earlier studies while primary endpoint missed. Press release, issued on July 9, 2009. www.medicalnewstoday.com/articles/156856.php. Accessed May 31, 2010.

160 AstraZeneca Pharmaceuticals Inc. European Commission approves Brilique (ticagrelor tablets). http://www.astrazeneca.com/Media/Press-releases/Article/European-Commission-Approves-Brilique. Accessed December 15, 2010.

161 Bates SM, Greer IA, Pabinger I, Sofaer S, Hirsh J. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6)(suppl):844S-886S.

162 Bauersachs R, Berkowitz SD, Brenner B, et al; EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. New Engl J Med. 2010;363(26):2499-2510.

163 Bavry AA, Kumbhani DJ, Rassi, AN, Bhatt DL, Askari AT. Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials J Am Coll Cardiol. 2006;48(7):1319-1325.

164 Bergmann JF, Cohen AT, Tapson VF, et al; ENDORSE Investigators. Venous thromboembolism risk and prophylaxis in hospitalised medically ill patients. The ENDORSE Global Survey. Thromb Haemost. 2010;103(4):736-748.

165 Boehringer Ingelheim. Pradax (gabidatran etexilate) gains approval in Canada for stroke prevention in atrial fibrillation. http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2010/27_october_2010_dabigatran.html. Accessed March 4, 2011.

166 Boersma E; Primary Coronary Angioplasty vs. Thrombolysis Group. Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. Eur Heart J. 2006;27(7):779-788.

167 Borris LC. New compounds in the management of venous thromboembolism after orthopedic surgery: focus on rivaroxaban. Vasc Health Risk Manag. 2008;4(4):855-862.

168 Brenner B. State of the art thrombosis prevention and treatment. Therapy. 2008;5(2):123-124.

169 Camm AJ, Kirchhof P, Lip GY, et al; European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369-2429.

170 Campbell IA, Bentley DP, Prescott RJ, Routledge PA, Shetty HG, Williamson IJ. Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both: randomised trial. BMJ. 2007;334(7595):674.

171 Committee for Medicinal Products for Human Use (CHMP). Public statement on possible interactions between clopidogrel and proton pump inhibitors. London, England: European Medicines Agency; 2009.

172 Committee for Medicinal Products for Human Use (CHMP). Monthly report, March 2010. London, England: European Medicines Agency; 2010.

173 Connolly SJ, Ezekowitz MD, Yusuf S, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. New Engl J Med. 2009;361(12):1139-1151.

174 Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L; Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators. Newly identified events in the RE-LY trial. N Engl J Med. 2010;363(19):1875-1876.

175 Connolly SJ, Pogue J, Hart RG, et al; ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009;360(20):2066–2078.

176 Connolly S, Pogue J, Hart R, et al; ACTIVE Writing Group on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367(9526):1903-1912.

177 Coulter SA. Echocardiographic evaluation of coronary artery disease. In: Willerson JT, Cohn NJ, Wellens HJ, Holmes DR Jr, eds. Cardiovascular Medicine. 3rd ed. London, England: Springer-Verlag London Limited; 2007:811-839.

178 Davizon P, López JA. Microparticles and thrombotic disease. Curr Opin Hematol. 2009;16(5):334-341.

179 Decousus H, Tapson VF, Bergmann JF, et al; IMPROVE Investigators. Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest. 2011;139(1):69-79.

180 Dennis M, Sandercock PA, Reid J, et al; CLOTS Trials Collaboration. Effectiveness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1): a multicentre, randomised controlled trial. Lancet. 2009;373(9679):1958-1965.

181 Dougu N, Takashima S, Sasahara E, et al. Differential diagnosis of cerebral infarction using an algorithm combining atrial fibrillation and D-dimer level. Eur J Neurol. 2008;15(3):295-300.

182 Dresang LT, Fontaine P, Leeman L, King VJ. Venous thromboembolism during pregnancy. Am Fam Physician. 2008;77(12):1709-1716.

183 Duke Clinical Research Institute website. ORBIT-A registry 2010. www.dukehealth.org. Accessed May 21, 2010.

184 Effient [package insert]. Indianapolis, IN: Eli Lilly & Company, Inc.; 2010.

185 Eichinger S, Minar E, Bialonczyk C, et al. D-dimer levels and risk of recurrent venous thromboembolism. JAMA. 2003;290(8):1071-1074.

186 Eikelboom JW, Zelenkofske SL, Rusconi CP. Coagulation factor IXa as a target for treatment and prophylaxis of venous thromboembolism. Arterioscler Thromb Vasc Biol. 2010;30(3):382-387.

187 Ellis DJ, Usman MH, Milner PG, Canafax DM, Ezekowitz MD. The first evaluation of a novel vitamin K antagonist, tecarfarin (ATI-5923), in patients with atrial fibrillation. Circulation. 2009;120(12):1029-1035.

188 Eriksson BI, Dahl OE, Lassen MR, et al; Fixit Study Group. Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study. J Thromb Haemost. 2008;6(3):457-463.

189 Eriksson BI, Dahl OE, Rosencher N, et al.; RE-MODEL Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007;5(11):2178-2185.

190 Eriksson BI, Dahl OE, Rosencher N, et al; RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007;370(9591):949-956.

191 Eriksson BI, Turpie AG, Lassen MR, et al. Once daily YM150, an oral direct Factor Xa inhibitor, for prevention of venous thromboembolism in patients undergoing elective primary hip replacement. Abstract of oral session presented at 49th American Society of Hematology Annual Meeting, Atlanta, Georgia, USA, December 8–11, 2007. Blood. 2007;110(11)(Part 1):309.

192 Ezekowitz MD, Reilly PA, Nehimz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol. 2007;100(9):1419-1426.

193 Fareed J, Wahi R, Hoppensteadt DA. An update on new anticoagulant drugs. East J Med. 2009;14(2):84-93.

194 Friedman RJ. New oral anticoagulants for thromboprophylaxis after elective total hip and knee arthroplasty. Thrombosis. 2010:1-9. Article ID 280731.

195 Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med. 2008;359(9):938-949.

196 Gaglia MA Jr, Manoukian SV, Waksman R. Novel antiplatelet therapy. Am Heart J. 2010;160(4):595-604.

197 Galanaud JP, Quenet S, Rivron-Guillot K, et al.; RIETE Investigators. Comparison of the clinical history of symptomatic isolated distal deep-vein thrombosis vs. proximal deep vein thrombosis in 11 086 patients. J Thromb Haemost. 2009;7(12):2028-2034.

198 Gasparyan AY. Aspirin and clopidogrel resistance: methodological challenges and opportunities. Vasc Health Risk Manag. 2010;6:109-112.

199 Goldhaber SZ. Cardiovascular medicine: XVIII. Venous thromboembolism. In: Dale DC, ed. ACP Medicine. New York, NY: WebMD, Inc; 2010:1-15.

200 Gurbel PA, Bliden KP, Antonino MJ, et al. The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients. J Thromb Haemost. 2010;8(1):43-53.

201 Haas S. New anticoagulants - towards the development of an "ideal" anticoagulant. Vasa. 2009;38(1):13-29.

202 Haines ST, Mitt DM, Nutescu EA. Venous thromboembolism. In: DiPiro J, Talbert R, Yee G, Matzke G, Wells G, Posey L, eds. Pharmacotherapy: A Pathophysiologic Approach. 7th ed. New York, NY: McGraw-Hill Companies Inc; 2008:331-371.

203 Hirsh J, Warkentin TE, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest. 1998;114(5)(suppl):489S-510S.

204 Hoffmann U, Bamberg F, Chae CU, et al. Coronary computed tomography angiography for early triage of patients with acute chest pain: the ROMICAT (Rule Out Myocardial Infarction using Computer Assisted Tomography) trial. J Am Coll Cardiol. 2009;53(18):1642–1650.

205 Holmes DR Jr, Kereiakes DJ, Kleiman NS, Moliterno DJ, Patti G, Grines CL. Combining antiplatelet and anticoagulant therapies. J Am Coll Cardiol. 2009;54(2):95-109.

206 Holmes DR, Reddy VY, Turi ZG, et al; PROTECT AF Investigators. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet. 2009;374(9689):534-542.

207 Hull, RD, Schellong, SM, Tapson, VF, et al; EXCLAIM (Extended Prophylaxis for Venous ThromboEmbolism in Acutely Ill Medical Patients With Prolonged Immobilization) Study. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med. 2010;153(1):8-18.

208 James AH. Pregnancy and thrombotic risk. Crit Care Med. 2010;38(2)(suppl):S57-S63.

209 Kakkar AK, Cohen AT, Tapson VF, et al; ENDORSE Investigators. Venous thromboembolism risk and prophylaxis in the acute care hospital setting (ENDORSE survey): findings in surgical patients. Ann Surg. 2010;251(2):330-338.

210 Kamath S, Blann AD, Chin BS, Lip GY. A prospective randomized trial of aspirin-clopidogrel combination therapy and dose-adjusted warfarin on indices of thrombogenesis and platelet activation in atrial fibrillation. J Am Coll Cardiol. 2002;40(3):484-490.

211 Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med. 1999;340(12):901-907.

212 Kearon C, Ginsberg JS, Anderson DR, et al; SOFAST Investigators. Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor. J Thromb Haemost. 2004;2(5):743-749.

213 Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003;361(9351):13-20.

214 Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902-4907.

215 Klein TE, Altman RB, Eriksson N, et al; International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009;360(8):753-764.

216 Kluge A, Mueller C, Strunk J, Lange U, Bachmann G. Experience in 207 combined MRI examinations for acute pulmonary embolism and deep vein thrombosis. AJR Am J Roentgenol. 2006;186(6):1686-1696.

217 Kuliczkowski W, Floyd J, Malinin A, Serebruany V. Aptamers: the emerging class of future anticoagulation for vascular disease. Expert Rev Cardiovasc Ther. 2010;8(4):503-507. http://www.medscape.com/viewarticle/722755_print. Accessed December 13, 2010.

218 Kyrle PA, Eichinger S. The risk of recurrent venous thromboembolism: the Austrian Study on Recurrent Venous Thromboembolism. Wien Klin Wochenschr. 2003;115(13-14):471-474.

219 Lang IM, Klepetko W. Chronic thromboembolic pulmonary hypertension: an updated review. Curr Opin Cardiol. 2008;23(6):555-559.

220 Lassen MR, Dahl OE, Mismetti P, Destrée D, Turpie AG. AVE5026, a new hemisynthetic ultra-low-molecular-weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery—TREK: a dose-ranging study. J Thromb Haemost. 2009;7(4):566-572.

221 Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM; ADVANCE-3 Investigators. Randomized double-blind comparison of apixaban and enoxaparin for thromboprophylaxis after hip replacement: the ADVANCE-3 Trial [Abstract OC356]. Presented at the 21st International Congress on Thrombosis, Milan, Italy, July 6-9, 2010. Pathophysiol Haemost Thromb. 2009/2010;37(suppl 1):A20.

222 Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P; ADVANCE-2 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010;375(9717):807-815.

223 Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. New Engl J Med. 2009;361(6):594-604.

224 Last EJ, Sheehan AH. Review of recent evidence: potential interaction between clopidogrel and proton pump inhibitors. Am J Health Syst Pharm. 2009;66(23):2117-2122.

225 Lee KW, Lip GY. Acute coronary syndromes: Virchow’s triad revisited. Blood Coagul Fibrinolysis. 2003;14(7):605-625.

226 Lip GY, Halperin JL. Improving stroke risk stratification in atrial fibrillation. Am J Med. 2010;123(6):484-488.

227 Lip GY, Huber K, Andreotti F, et al; European Society of Cardiology Working Group on Thrombosis. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary—a consensus document of the European Society of Cardiology Work Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2010;31(11):1311-1318.

228 Lip GY, Lim HS. Atrial fibrillation and stroke prevention. Lancet Neurol. 2007;6(11):981-993.

229 Lip GY, Lowe GD. Fibrin D-dimer: a useful clinical marker of thombogenesis? Clin Sci (Lond). 1995;89(3):205-214.

230 Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263-272.

231 Lloyd-Jones D, Adams RJ, Brown TM, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation. 2010;121(7):e46-e215.

232 Lockie T, Nagel E, Redwood S, Plein S. Use of cardiovascular magnetic resonance imaging in acute coronary syndromes. Circulation. 2009;119(12):1671-1681.

233 Lyman GH. Venous thromboembolism in the patient with cancer. Focus on burden of disease and benefits of thromboprophylaxis. Cancer. Nov 2010. Epub ahead of print.

234 Lyman GH, Khorana AA, Falanga A, et al; American Society of Clinical Oncology. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007;25(34):5490-5505.

235 Mackman N, Becker RC. DVT: a new era in anticoagulant therapy. Arterioscler Thromb Vasc Biol. 2010;30(3);369-371.

236 Mahaffey KW, Fox KA. Stroke prevention using the oral direct Factor Xa inhibitor rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation (ROCKET AF) [trial slide deck]. Late-breaking clinical trial presented at the 2010 American Heart Association Scientific Session, Chicago, IL, USA, 15 November 2010.

237 Mahé I, Drouet L, Simoneau G, Minh-Muzeaux S, Caulin C, Bergmann JF. D-dimer can predict survival in patients with chronic atrial fibrillation. Blood Coagul Fibrinolysis. 2004;15(5):413-417.

238 Mant J, Hobbs FD, Fletcher K, et al; Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007;370(9586):493-503.

239 Mehta RS. Novel oral anticoagulants for prophylaxis and treatment of venous thromboembolism: part I (Factor Xa inhibitors). Expert Rev Hematol. 2010:3(2):227–241.

240 Michelson AD. New P2Y12 antagonists. Curr Opin Hematol. 2009;16(5):371-377.

241 Miller GJ, Ireland HA, Cooper JA, et al. Relationship between markers of activated coagulation, their correlation with inflammation, and association with coronary heart disease (NPHSII). J Thromb Haemost. 2008;6(2):259-267.

242 Mitsubishi Pharma Europe Ltd. Argatroban Introduction. http://www.argatroban.eu/index2.php?page=24#. Accessed December 10, 2010.

243 Montalescot G, Wiviott SD, Braunwald E, et al; TRITON-TIMI 38 investigators. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised, controlled trial. Lancet. 2009;373(9665):723-731.

244 Mousa SA, Jeske WP, Fareed J. Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist. Clin Appl Thromb Hemost. 2010;16(2):170-176.

245 National Institute for Health and Clinical Excellence. Final appraisal determination: Prasugrel for the treatment of acute coronary syndromes with percutaneous coronary intervention. London, England: National Clinical Guideline Centre; 2009.

246 National Institute for Health and Clinical Effectiveness. Venous thromboembolism: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital. London, England: National Clinical Guideline Centre – Acute and Chronic Conditions; 2010.

247 Ng TM, Tsai F, Khatri N, Barakat MN, Elkayam U. Venous thromboembolism in hospitalized patients with heart failure: incidence, prognosis, and prevention. Circ Heart Fail. 2010;3(1):165-173.

248 Pabinger I, Ay C. Biomarkers and venous thromboembolism. Arterioscler Thromb Vasc Biol. 2009;29(3):332-336.

249 Paul Coverdell National Acute Stroke Registry. http://www.cdc.gov/dhdsp/programs/stroke_registry.htm. Accessed December 10, 2010.

250 Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093-1100.

251 Pradaxa [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals; 2010.

252 Price MJ, Endemann S, Gollapudi RR, et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J. 2008;29(8):992-1000.

253 Rash A, Downes T, Portner R, Yeo WW, Morgan N, Channer KS. A randomized controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). Age Ageing. 2007;36(2):151-156.

254 RecordAF registry. www.recordaf.org. Accessed May 11, 2010.

255 Refludan [package insert]. Wayne, NJ: Bayer HealthCare Pharmaceuticals; 2007.

256 Ricciardi MJ, Boehar N, Davidson CJ. Cardiac catheterization and coronary angiography. In: Rosendoff C, ed. Essential Cardiology: Principles and Practices. 2nd ed. Totowa, NJ: Humana Press; 2005:197-219.

257 Sadanaga T, Sadanaga M, Ogawa S. Evidence that D-dimer levels predict subsequent thromboembolic and cardiovascular events in patients with atrial fibrillation during oral anticoagulant therapy. J Am Coll Cardiol. 2010;55(20):2225-2231.

258 Sampson FC, Goodacre SW, Thomas SM, van Beek EJ. The accuracy of MRI in diagnosis of suspected deep vein thrombosis: systematic review and meta-analysis. Eur Radiol. 2007;17(1):175-181.

259 Sato H, Ishikawa K, Kitabatake A, et al; Japan Atrial Fibrillation Stroke Trial Group. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. Stroke. 2006;37(2):447-451.

260 Scarabin PY, Arveiler D, Amouyel P, et al; Prospective Epidemiological Study of Myocardial Infarction. Plasma fibrinogen explains much of the difference in risk of coronary heart disease between France and Northern Ireland. The PRIME study. Atherosclerosis. 2003;166(1):103-109.

261 Schulman S, Kearon C, Kakkar AK, et al; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. New Engl J Med. 2009;361(24):2342-2352.

262 Scirica BM. Acute coronary syndrome: emerging tools for diagnosis and risk assessment. J Am Coll Cardiol. 2010;55(14):1403-1415.

263 Summary of product characteristics for Angiox. London, England: European Medicines Agency; 2009.

264 Summary of product characteristics for Arixtra. London, England: European Medicines Agency; 2007.

265 Summary of product characteristics for Effient. London, England: European Medicines Agency; 2010.

266 Summary of product characteristics for Plavix. London, England: European Medicines Agency; 2010.

267 Summary of product characteristics for Pradaxa. London, England: European Medicines Agency; 2008.

268 Summary of product characteristics for Refludan. London, England: European Medicines Agency; 2009.

269 Summary of product characteristics for Xarelto. London, England: European Medicine Agency; 2008.

270 Sweetland S, Green J, Liu B, et al; Million Women Study collaborators. Duration and magnitude of the postoperative risk of venous thromboembolism in middle aged women: prospective cohort study. BMJ. 2009;339:b4583.

271 Themistoclakis S, Corrado A, Marchlinski FE, et al. The risk of thromboembolism and need for oral anticoagulation after successful atrial fibrillation ablation. J Am Coll Cardiol. 2010;55(8):735-743.

272 Thistlethwaite PA, Kaneko K, Madani MM, Jamieson SW. Technique and outcomes of pulmonary endarterectomy surgery. Ann Thorac Cardiovasc Surg. 2008;14(5):274-282.

273 Thomas DP, Roberts HR. Hypercoagulability in venous and arterial thrombosis. Ann Intern Med. 1997;126(8):638-644.

274 Thrombosis Research Institute website. www.tri-london.ac.uk/research-Garfield.asp. Accessed May 19, 2010.

275 US Food and Drug Administration. Information on clopidogrel bisulphate (marketed as Plavix). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm190836.htm. Accessed December 15, 2010.

276 van Belle A, Büller HR, Huisman MV, et al; Christopher Study Investigators. Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography. JAMA. 2006;295(2):172-179.

277 Vene N, Mavri A, Kosmelj K, Stegnar M. High D-dimer levels predict cardiovascular events in patients with chronic atrial fibrillation during oral anticoagulant therapy. Thromb Haemost. 2003;90(6):1163-1172.

278 Vormittag R, Panzer S, Ay C, Quehenberger P, Koder S, Pabinger I. Soluble P-selectin and thrombosis risk of patients with a persistent lupus anticoagulant in a prospective cohort study [abstract 0878]. Haematologica. 2007;92(suppl 2):327.

279 Wallentin L, Becker RC, Budaj A, et al; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. New Engl J Med. 2009;361(11):1045-1057.

280 Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow’s triad revisited. Lancet. 2009;373(9658):155-166.

281 Weitz JI, Connolly SJ, Patel I, et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010;104(3):633-641.

282 Wells PS, Ginsberg JS, Anderson DR, et al. Use of a clinical model for safe management of patients with suspected pulmonary embolism. Ann Intern Med. 1998;129(12):997–1005.

283 Wells P, Anderson DR, Rodger M, et al. Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost. 2000;83(3):416–420.

284 Wells PS, Anderson DR, Rodger M, et al. Excluding pulmonary embolism at the bedside without diagnostic imaging: management of patients with suspected pulmonary embolism presenting to the emergency department by using a simple clinical model and d-dimer. IAnn Intern Med. 2001;135(2):98–107.

285 Wijns W, Kolh P, Danchin N, et al; European Association for Percutaneous Cardiovascular Interventions. Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2010;31(20):2501-2555.

286 Wilson RF, White CW. Coronary angiography. In: Willerson JT, Cohn JN, Wellens HJJ, Holmes DR Jr, eds. Cardiovascular Medicine. 3rd ed. London, England: Springer-Verlag London Limited; 2007:745-810.

287 Wolf PA, Dawber TR, Thomas HE Jr, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham Study. Neurology. 1978;28(10):973-977.

288 Zhu T, Martinez I, Emmerich J. Venous thromboembolism: risk factors for recurrence. Arterioscler Thromb Vasc Biol. 2009;29(3):298–310.

289 Kannel WB, Benjamin EJ. Status of the epidemiology of atrial fibrillation. Med Clin North Am. 2008 Jan;92(1):17-40

290 Myasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114(2):119-125.

291 Inoue H, Fujiki A, Origasa H, Ogawa S, et al., Prevalence of atrial fibrillation in the general population of Japan: an analysis based on periodic health examination. Int J Cardiol. 2009 Oct 2;137(2):102-7. Epub 2008 Aug 8.